Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation

Jennifer H. Cao, Matthew Mulvahill, Li Zhang, Brian C. Joondeph, Mark S. Dacey

Research output: Contribution to journalArticle

47 Scopus citations

Abstract

Purpose: To examine the observational effectiveness of the dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) in the treatment of noninfectious uveitic macular edema in patients with otherwise quiescent uveitis.

Design: Retrospective chart review.

Participants: A total of 27 consecutive patients with persistent macular edema resistant to standard shortterm therapy despite quiescent noninfectious intermediate or posterior uveitis.

Methods: Each patient was treated with a DEX 0.7 mg implant.

Main Outcome Measures: Primary outcome measure was resolution of macular edema 1 month after injection as measured by decrease in central macular thickness (CMT). Secondary outcome was change in visual acuity 1, 2, and 3 months after injection.

Results: A total of 27 eyes of 27 patients were included for analysis. One eye was randomly selected for 6 of these patients who received bilateral DEX implants. There was a statistically significant reduction in mean CMT 1 month after DEX implantation (mean, 278.9 μm; range, 206-352 μm) compared with baseline (mean, 478.7 μm; range, 330-667 μm) (P < 0.0001). There was a statistically significant improvement in visual acuity at 3 months (logarithm of the minimum angle of resolution [logMAR] 0.41; 20/51) compared with baseline (logMAR 0.60; 20/80) (P = 0.0005). There were no major complications after DEX implantation.

Conclusions: The DEX implant resulted in a statistically significant improvement in mean CMT and visual acuity without any serious adverse events.

Original languageEnglish (US)
Pages (from-to)1871-1876
Number of pages6
JournalOphthalmology
Volume121
Issue number10
DOIs
StatePublished - Oct 1 2014

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation'. Together they form a unique fingerprint.

  • Cite this